Phoenix, Arizona (PRWEB) April 28, 2014

Center for Joint Regeneration is now offering stem cell procedures for nonoperative rotator cuff repair with Board Certified orthopedic doctors. The regenerative medicine procedures are performed as an outpatient and involve either bone marrow derived or amniotic derived stem cell material. Call (480) 466-0980 for more information and scheduling.

Millions of Americans are affected by shoulder pain due to a rotator cuff bursitis or tendon tear. The pain may persist for months and may end up needing surgery if traditional treatments fail. These may include steroid injections, physical therapy and pain medication.

Treatment with regenerative medicine has now become available with stem cell material. The Board Certified orthopedic doctors at Center for Joint Regeneration offer stem cell procedures for rotator cuff injuries with either bone marrow or amniotic derived stem cells.

The bone marrow stem cells involve harvesting the material in a short procedure from the patient, with immediate processing to concentrate the stem cells and growth factors for injection into the shoulder. The amniotic material is obtained from consenting donors after a scheduled c-section procedure. There is no fetal tissue used at all, alleviating any ethical concerns.

Small studies to date have shown stem cell procedures to work well for pain relief and restoration of function with musculoskeletal conditions such as knee arthritis, ligament injury and tendonitis. The stem cell material includes growth factors, stem cells, hyaluronic acid and anti-inflammatory medicine as well.

Center for Joint Regeneration also offers stem cell procedures for joint arthritis, ligament injuries and tendonitis of other areas of the body as well. This helps patients avoid surgery as well as helping athletes return to sporting activities.

For more information and scheduling to discuss regenerative medicine stem cell procedure options, call (480) 466-0980.

See more here:
Center for Joint Regeneration in Phoenix Now Offering Stem Cell Procedures for Nonoperative Rotator Cuff Tendon Repair

An international team led by King's College London and the San Francisco Veteran Affairs Medical Center (SFVAMC) has developed the first lab-grown epidermis -- the outermost skin layer -- with a functional permeability barrier akin to real skin. The new epidermis, grown from human pluripotent stem cells, offers a cost-effective alternative lab model for testing drugs and cosmetics, and could also help to develop new therapies for rare and common skin disorders.

The epidermis, the outermost layer of human skin, forms a protective interface between the body and its external environment, preventing water from escaping and microbes and toxins from entering. Tissue engineers have been unable to grow epidermis with the functional barrier needed for drug testing, and have been further limited in producing an in vitro (lab) model for large-scale drug screening by the number of cells that can be grown from a single skin biopsy sample.

The new study, published in the journal Stem Cell Reports, describes the use of human induced pluripotent stem cells (iPSC) to produce an unlimited supply of pure keratinocytes -- the predominant cell type in the outermost layer of skin -- that closely match keratinocytes generated from human embryonic stem cells (hESC) and primary keratinocytes from skin biopsies. These keratinocytes were then used to manufacture 3D epidermal equivalents in a high-to-low humidity environment to build a functional permeability barrier, which is essential in protecting the body from losing moisture, and preventing the entry of chemicals, toxins and microbes.

A comparison of epidermal equivalents generated from iPSC, hESC and primary human keratinocytes (skin cells) from skin biopsies showed no significant difference in their structural or functional properties compared with the outermost layer of normal human skin.

Dr Theodora Mauro, leader of the SFVAMC team, says: "The ability to obtain an unlimited number of genetically identical units can be used to study a range of conditions where the skin's barrier is defective due to mutations in genes involved in skin barrier formation, such as ichthyosis (dry, flaky skin) or atopic dermatitis. We can use this model to study how the skin barrier develops normally, how the barrier is impaired in different diseases and how we can stimulate its repair and recovery."

Dr Dusko Ilic, leader of the team at King's College London, says: "Our new method can be used to grow much greater quantities of lab-grown human epidermal equivalents, and thus could be scaled up for commercial testing of drugs and cosmetics. Human epidermal equivalents representing different types of skin could also be grown, depending on the source of the stem cells used, and could thus be tailored to study a range of skin conditions and sensitivities in different populations."

Story Source:

The above story is based on materials provided by King's College London. Note: Materials may be edited for content and length.

View post:
Skin layer grown from human stem cells could replace animals in drug, cosmetics testing

PUBLIC RELEASE DATE:

23-Apr-2014

Contact: Nicanor Moldovan Moldovan.6@osu.edu 614-247-7801 Ohio State University

COLUMBUS, Ohio New research suggests that attempts to isolate an elusive adult stem cell from blood to understand and potentially improve cardiovascular health a task considered possible but very difficult might not be necessary.

Instead, scientists have found that multiple types of cells with primitive characteristics circulating in the blood appear to provide the same benefits expected from a stem cell, including the endothelial progenitor cell that is the subject of hot pursuit.

"There are people who still dream that the prototypical progenitors for several components of the cardiovascular tree will be found and isolated. I decided to focus the analysis on the whole nonpurified cell population the blood as it is," said Nicanor Moldovan, senior author of the study and a research associate professor of cardiovascular medicine at The Ohio State University.

"Our method determines the contributions of all blood cells that serve the same function that an endothelial progenitor cell is supposed to. We can detect the presence of those cells and their signatures in a clinical sample without the need to isolate them."

The study is published in the journal PLOS ONE.

Stem cells, including the still poorly understood endothelial progenitor cells, are sought-after because they have the potential to transform into many kinds of cells, suggesting that they could be used to replace damaged or missing cells as a treatment for multiple diseases.

By looking at gene activity patterns in blood, Moldovan and colleagues concluded that many cell types circulating throughout the body may protect and repair blood vessels a key to keeping the heart healthy.

Continued here:
Stem cells in circulating blood affect cardiovascular health, study finds

Low back and neck pain; 6 months after stem cell therapy by Dr Harry Adelson
Low back and neck pain; 6 months after stem cell therapy by Dr Harry Adelson http://www.docereclinics.com.

By: Harry Adelson, N.D.

Read the original post:
Low back and neck pain; 6 months after stem cell therapy by Dr Harry Adelson - Video

Watch the Cancer.Net Video: Bone Marrow and Stem Cell Transplantation: An Introduction, with Sonali Smith, MD, adapted from this content.

Key Messages:

Stem cell transplantation is a procedure that is most often recommended as a treatment option for people with leukemia, multiple myeloma, and some types of lymphoma. It may also be used to treat some genetic diseases that involve the blood.

During a stem cell transplant diseased bone marrow (the spongy, fatty tissue found inside larger bones) is destroyed with chemotherapy and/or radiation therapy and then replaced with highly specialized stem cells that develop into healthy bone marrow. Although this procedure used to be referred to as a bone marrow transplant, today it is more commonly called a stem cell transplant because it is stem cells in the blood that are typically being transplanted, not the actual bone marrow tissue.

The purpose of bone marrow and hematopoietic (blood-forming) stem cells

Bone marrow produces more than 20 billion new blood cells every day throughout a person's life. The driving force behind this process is the hematopoietic (pronounced he-mah-tuh-poy-ET-ick) stem cell. Hematopoietic stem cells are immature cells found in both the bloodstream and bone marrow. These specialized cells have the ability to create more blood-forming cells or to mature into one of the three different cell types that make up our blood. These include red blood cells (cells that carry oxygen to all parts of the body), white blood cells (cells that help the body fight infections and diseases), and platelets (cells that help blood clot and control bleeding). Signals passing from the body to the bone marrow tell the stem cells which cell types are needed the most.

For people with bone marrow diseases and certain types of cancer, the essential functions of red blood cells, white blood cells, and platelets are disrupted because the hematopoietic stem cells dont mature properly. To help restore the bone marrows ability to produce healthy blood cells, doctors may recommend stem cell transplantation.

Types of stem cell transplantation

There are two main types of stem cell transplantation:

Autologous transplantation (AUTO). A patient undergoing an AUTO transplant receives his or her own stem cells. During the AUTO transplant process, the patients stem cells are collected and then stored in a special freezer that can preserve them for decades. Usually the patient is treated the following week with powerful doses of chemotherapy and/or radiation therapy, after which the frozen stem cells are thawed and infused into the patient's vein. The stem cells typically remain in the bloodstream for about 24 hours until they find their way to the marrow space, where they grow and multiply, beginning the healing process.

More here:
What is Stem Cell/Bone Marrow Transplantation? | Cancer.Net

Madison #39;s Before After Stem Cell Therapy
Had step cell therapy procedure on 4/14/14 and we were seeing noticeable results only 4 short days later.

By: Jaie Locke

Read more:
Madison's Before & After Stem Cell Therapy - Video

Researchers announced today that tissue engineering has been used to construct natural esophagi which in combination with bone marrow stem cells have been safely and effectively transplanted in rats, according to a study published in the prestigious online journal, Nature Communications. The study shows that the transplanted organs remain patent and display regeneration of nerves, muscles, epithelial cells and blood vessels.

The new method was developed by researchers at Karolinska Institutet in Sweden, within an international collaboration lead by Professor Paolo Macchiarini, and including Doris Taylor, MD, Director of Regenerative Medicine Research at the Texas Heart Institute (THI).

We are very excited and honored to be a part of the team taking such heroic steps, that will ultimately benefit so many patients throughout the world, said Dr. Taylor, who is leading ground-breaking organ-building work at THI that may ultimately lead to the ability to grow new hearts and other organs using a patients own stem cells.

Dr. Taylor has collaborated with Professor Macchiarini for several years, and they have jointly published previous papers on tissue engineering. THI and Dr. Taylor are in the midst of multiple international collaborations in this field, and she also serves on a committee named by Texas Medical Center (TMC) President Robert Robbins, MD, to help guide regenerative medicine research throughout TMC.

The joint goal is to discover, develop, and take first steps toward delivering a more complex tissue, such as a heart, added Dr. Taylor. We see this as another important milestone along that path, which we expect will ultimately help many millions of patients.

James T. Willerson, MD, President, THI added This is a very important step forward toward the goal of regenerating tissues using Dr. Taylors methods. The ability to regenerate a patients esophagus after it has been injured, will help many people. The same is true for an injured heart.

The technique to grow human tissues and organs so called tissue engineering has been employed so far to produce urinary bladder, trachea and blood vessels, which have also been used clinically. However, despite several attempts, it has been proven difficult to grow tissue to replace a damaged esophagus.

In this new study, the researchers created the bioengineered organs by soaking esophagi from rats to remove all the cells. With the cells gone, a scaffold remains in which the structure as well as mechanical and chemical properties of the organ are preserved. The produced scaffolds were then reseeded with cells from the bone marrow of the recipient. The adhering cells have low immunogenicity, which minimizes the risk of immune reaction and graft rejection and also eliminates the need for immunosuppressive drugs. The cells adhered to the biological scaffold and started to show organ-specific characteristics within three weeks.

The cultured tissues were used to replace segments of the esophagus in rats. All rats survived and after two weeks the researchers found indications of the major components in the regenerated graft: epithelium, muscle cells, blood vessels and nerves.

We believe that these very promising findings represent major advances towards the clinical translation of tissue engineered esophagi, said Paolo Macchiarini, Director of Advanced Center for Translational Regenerative Medicine (ACTREM) at Karolinska Institutet.

Read the original here:
Dr. Taylor assists international team of researchers achieve milestone by tissue engineering construction of esophagus

Researchers announced today that tissue engineering has been used to construct natural esophagi which in combination with bone marrow stem cells have been safely and effectively transplanted in rats, according to a study published in the prestigious online journal, Nature Communications. The study shows that the transplanted organs remain patent and display regeneration of nerves, muscles, epithelial cells and blood vessels.

The new method was developed by researchers at Karolinska Institutet in Sweden, within an international collaboration lead by Professor Paolo Macchiarini, and including Doris Taylor, MD, Director of Regenerative Medicine Research at the Texas Heart Institute (THI).

We are very excited and honored to be a part of the team taking such heroic steps, that will ultimately benefit so many patients throughout the world, said Dr. Taylor, who is leading ground-breaking organ-building work at THI that may ultimately lead to the ability to grow new hearts and other organs using a patients own stem cells.

Dr. Taylor has collaborated with Professor Macchiarini for several years, and they have jointly published previous papers on tissue engineering. THI and Dr. Taylor are in the midst of multiple international collaborations in this field, and she also serves on a committee named by Texas Medical Center (TMC) President Robert Robbins, MD, to help guide regenerative medicine research throughout TMC.

The joint goal is to discover, develop, and take first steps toward delivering a more complex tissue, such as a heart, added Dr. Taylor. We see this as another important milestone along that path, which we expect will ultimately help many millions of patients.

James T. Willerson, MD, President, THI added This is a very important step forward toward the goal of regenerating tissues using Dr. Taylors methods. The ability to regenerate a patients esophagus after it has been injured, will help many people. The same is true for an injured heart.

The technique to grow human tissues and organs so called tissue engineering has been employed so far to produce urinary bladder, trachea and blood vessels, which have also been used clinically. However, despite several attempts, it has been proven difficult to grow tissue to replace a damaged esophagus.

In this new study, the researchers created the bioengineered organs by soaking esophagi from rats to remove all the cells. With the cells gone, a scaffold remains in which the structure as well as mechanical and chemical properties of the organ are preserved. The produced scaffolds were then reseeded with cells from the bone marrow of the recipient. The adhering cells have low immunogenicity, which minimizes the risk of immune reaction and graft rejection and also eliminates the need for immunosuppressive drugs. The cells adhered to the biological scaffold and started to show organ-specific characteristics within three weeks.

The cultured tissues were used to replace segments of the esophagus in rats. All rats survived and after two weeks the researchers found indications of the major components in the regenerated graft: epithelium, muscle cells, blood vessels and nerves.

We believe that these very promising findings represent major advances towards the clinical translation of tissue engineered esophagi, said Paolo Macchiarini, Director of Advanced Center for Translational Regenerative Medicine (ACTREM) at Karolinska Institutet.

Read more:
International team of researchers engineer construction of esophagus

Researchers say they have made powerful stem cells from both young and old adults using cloning techniques, and also found clues about why it is so difficult to do this with human beings.

The team, at Massachusetts-based Advanced Cell Technology and the Institute for Stem Cell Research in Los Angeles, say they used the cloning methods to create the stem cells to match a 35-year-old man and a 75-year-old man.

They used a bit of skin from each man, took the DNA from the skin cells and inserted it into the egg cell of a female donor, and grew very early embryos called blastocysts, the team reports in the journal Cell Stem Cell. Cells from these embryos closely match the men and could, in theory, be used to make near-identical tissue, blood or organ transplants for the men.

If verified, it would be only the second confirmed time someones been able to use cloning methods to make human embryonic stem cells, considered the bodys master cells.

Therapeutic cloning has long been envisioned as a means for generating patient-specific stem cells that could be used to treat a range of age-related diseases, said Dr. Robert Lanza, chief scientific officer for Advanced Cell Technology.

However, despite cloning success in animals, the derivation of stem cells from cloned human embryos has proven elusive. Only one group has ever succeeded, and their lines were generated using fetal and infant cells.

That was last year, at Oregon Health & Science University.

When human embryonic stem cells were first discovered in 1998, scientists immediately dreamed of using cloning technology to help people grow their own organ and tissue transplants, and to use them to study disease. Theyd be perfect genetic matches for each patient, meaning an end to a lifetime of taking dangerous immune-suppressing drugs after an organ transplant.

But in the many years since, no labs been able to do the work easily. It seems it is much harder to clone a human being than it is to clone a sheep, a frog or a mouse.

And using the cloning technique is controversial, because it involves creating, then destroying, a human embryo.

See the article here:
Group Makes Stem Cells Using Clone Technique

By Estel Grace Masangkay

Researchers from the University of Michigan have discovered how mechanical forces in the environment influence stem cell growth and differentiation. The scientists arrived at the findings using a key ingredient in Silly Putty for their experiments.

Using an ultrafine carpet made out of polydimethylsiloxane, a key ingredient in Silly Putty, the scientists were able to coax stem cells to morph into working spinal cord cells. The Silly Putty component was made into a specially engineered growth system with microscopic posts. By varying the post height, the researchers were able to adjust the stiffness of the surface where the cells are made to grow.

Jianping Fu, assistant professor of mechanical engineering at the University of Michigan, said, This is extremely exciting. To realize promising clinical applications of human embryonic stem cells, we need a better culture system that can reliably produce more target cells that function well. Our approach is a big step in that direction, by using synthetic microengineered surfaces to control mechanical environmental signals.

Stem cells that were grown on tall, softer micropost carpets morphed into nerve cells faster and more often than those grown on stiffer surfaces. The colonies of spinal cord cells that grew on softer micropost carpets were also 10 times larger and four times more pure than those grown on rigid carpets or traditional plates.

The study is the first to directly link physical signals to human embryonic stem cells differentiation, in contrast to chemical signals. Professor Jianping Fu says the findings may lead to a more efficient way of guiding stem cells to differentiate and provide specialized therapies for diseases such Alzheimers, Huntingtons, Lou Gerhrigs disease, and others. Our work suggests that physical signals in the cell environment are important in neural patterning, a process where nerve cells become specialized for their specific functions based on their physical location in the body, said Professor Jianping.

The study from the University of Michigan was published online at Nature Materials this week.

See original here:
U-M Researchers Use Silly Putty Ingredient To Study Stem Cells

Washington (PRWEB) April 15, 2014

Research that resulted in the first stem cells that are pluripotentthose that have the potential to differentiate into almost any cell in the bodywill be the backdrop for a discussion about trends in regulation in the field of regenerative medicine at the DIA 2014 50th Annual Meeting, June 15 to 19 in San Diego.

Chaired by Shinji Miyake, professor of clinical research for the Keio University School of Medicine in Japan, the session Pioneering Regenerative Medicine: Trends in Regulations for New Therapy will introduce the worlds first clinical research of induced pluripotent stem (iPS) cell products, conducted in Japan, and review updated regulatory guidance to bring regenerative medicine to patients who need healthy tissue or organs. The session will be held June 16 at 8:30 a.m. in the San Diego Convention Center.

iPS cells are stem cells that can be generated directly from adult cells. These cells can multiply indefinitely and represent a single source of cells, such as heart, neural, pancreatic and liver, that can be used to replace damaged cells.

In 2006, Japanese physician and researcher Shinya Yamanaka led a team to generate iPS cells from adult mouse tissue using gene therapy. This work led to a Nobel Prize in Physiology or Medicine in 2012 for the discovery that mature cells can be reprogrammed to become pluripotent.

We are honored to host pioneers of this unique field of medicine at the DIA Annual Meeting to share their experiences in the planning of the first clinical research of iPS cell productswhich have the ability to enhance research worldwide, said Barbara L. Kunz, DIA global chief executive. Their expert knowledge of issues and solutions in the application of the regenerative therapies will benefit all who advocate for and drive innovative medicine.

The session will also feature a presentation about the application of iPS cells to retinal diseases by Masayo Takahashi, project leader for the RIKEN Center for Developmental Biology in Japan, along with a European Medicines Agency (EMA) presentation by Dariusz Sladowski, researcher and member of the Committee for Advanced Therapies at EMA.

ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIAs network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Pa., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit http://www.diahome.org.

ABOUT DIAs 2014 50th ANNUAL MEETING: Celebrate the Past Invent the Future is the largest multidisciplinary event that brings together a community of life sciences professionals at all levels and across all disciplines involved in the discovery, development and life cycle management of medical products. The meeting aims to foster innovation that will lead to the development of safe and effective medical products and therapies for patients. For more information, visit http://www.diahome.org/dia2014.

View post:
Pioneers in Regenerative Therapy to Discuss New Trends in Stem Cell Medicine

A key element of the popular children's toy Silly Putty could help scientists develop stem cell treatments for nerve and brain disorders such as motor neurone disease and Alzheimer's, a study suggests.

Researchers used the molecule that gives Silly Putty its unusual properties to grow working spinal cord cells on a soft, ultra-fine carpet.

They found that motor nerves grew faster and more often on the material than they did on a normal rigid surface.

The neurones also showed electrical activity comparable with that of motor nerves in the body.

The study is the first to show that physical, as well as chemical, signals directly affect the development of human embryonic stem cells.

Silly Putty, created by accident during Second World War research into potential rubber substitutes, bounces but also flows like a liquid and breaks when hit sharply.

A silicone polymer molecule called polydimethylsiloxane (PDMS) is mainly responsible for the odd properties that have made Silly Putty a hit with children around the world.

The new research involved coaxing embryonic stem cells to grow and develop on a soft "carpet" made from PDMS threads.

After 23 days, colonies of spinal cord motor neurones appeared that were four times purer and 10 times larger than those grown on traditional plates.

Lead scientist Dr Jianping Fu, from the University of Michigan in Ann Arbor, said: "This is extremely exciting. To realise promising clinical applications of human embryonic stem cells, we need a better culture system that can reliably produce more target cells that function well.

Excerpt from:
Weird Life

Cancer survivor to run London Marathon with his life-saver

11:00am Saturday 12th April 2014 in News

A BONE marrow donor will run Sundays London Marathon with the man whose life he saved.

Sean Hagan, 23, donated his stem cells after being inspired by Ulverston teenager Alice Pyne, who put it at the top of her bucket list before her tragic death from cancer in 2013.

The Askam-in-Furness mans donation saved the life of father-of-two Johnny Pearson, 44, from North Yorkshire, after he was diagnosed with leukaemia for the second time in just 18 months.

Sean, whose stem cell donation was undertaken by the Anthony Nolan charity, said: I remember being amazed at how simple it was. I hope Alice Pynes parents will see this and know what a special daughter they had. She was the reason I joined the Anthony Nolan register in the first place.

"Saving Johnnys life is the best thing Ive ever done and its the best thing Ill ever do.

The two men were allowed to write to each other anonymously and shared a series of emotional letters in which Johnny told Sean he wanted to shake his hand and show him what his donation means to his wife, children and friends.

They subsequently arranged to run the London Marathon together on Sunday.

Anthony Nolan, a charity that has been matching donors to recipients for 40 years, arranged for the pair to meet up for a training session before they undertake the 26.2 mile slog through the capital.

Read the original here:
Cancer survivor to run London Marathon with his life-saver

Stem Cell Therapy After Spinal Cord Injury
3D animation showing cell-replacement therapy after spinal cord injury. Animation done for Dr. Fehlings, Krembil Neuroscience Research Centre, Toronto, Ontario.

By: Synapse Medical Animation

See the original post:
Stem Cell Therapy After Spinal Cord Injury - Video

13 hours ago Isolated planarian pharynx: two tissue types in this digestive organ are shown. In red, cilia of the epithelial layer ensheathing the organ are labeled with an antibody against acetylated tubulin. In green, the complex longitudinal and circular muscle fibers are shown as labeled by the anti-myosin heavy chain antibody Tmus-13. Credit: Carrie Adler, Ph.D., Stowers Institute for Medical Research

As multicellular creatures go, planaria worms are hardly glamorous. To say they appear rudimentary is more like it. These tiny aquatic flatworms that troll ponds and standing water resemble brown tubes equipped with just the basics: a pair of beady light-sensing "eyespots" on their head and a feeding tube called the pharynx (which doubles as the excretory tract) that protrudes from a belly sac to suck up food. It's hard to feel kinship with them.

But admiration is another thing, because many planaria species regenerate in wondrous waysnamely, when quartered they reconstruct themselves from the pieces. Sliced through the "waist", they regenerate the missing tail or head; bisected lengthwise, worms duplicate their mirror image. This capacity is not what's surprising, as biologists know that 30% of their body cells are stem cells. The question is, how do stem cells in a planaria fragment know how to generate what's missing?

In the April 15, 2014 issue of the online journal eLife, Stowers Institute for Medical Research Investigator Alejandro Snchez Alvarado and colleagues address that issue by identifying genes worms use to rebuild an amputated pharynx. They report that near the top of the pharynx regeneration hierarchy is a master regulator called FoxA. These findings support an evolutionarily conserved role for FoxA proteins in driving construction of endoderm-derived organs and reveal how stem cells sense loss of a particular structure on a molecular level.

Mammals can deploy adult stem cells to replace skin or immune system cells, among others. But when it comes to re-creating entire structures, amphibian, fish and planarian species are the champs. "When mammals are severely injured, they just heal the wound and call it a day," says Snchez Alvarado, who is also a Howard Hughes Medical Institute Investigator. "But if a salamander loses a limb, it will first heal the wound and then start assembling the missing parts. Right now, the mechanisms cells use to realize what structure is missing and then restore it remain completely mysterious."

To unravel the mystery, the team conducted two "screens". First, they amputated the worm pharynx, which prohibits feeding for about a week as planaria rebuild a new one. Around day 3 post-amputation, the team conducted microarray analysis to identify any gene switched on by amputation and amassed about 350 candidates. To test them, they then fed inhibitory RNAs designed to suppress expression of each gene separately to new batches of worms, repeated the amputations and observed whether worms regained feeding ability. That narrowed the list to 20 candidates that when lost hampered feeding and in most cases interfered with pharynx formation.

According to Carrie Adler, Ph.D., a postdoctoral fellow in the Snchez Alvarado lab who led the study, analysis showed most of the 20 factors either had a generic function in stem cells (which was interesting but not what they were after) or were specifically required for pharynx regeneration. Among the latter, one factor showing a particularly robust effect was a DNA-binding protein called FoxA. "Targeting FoxA completely blocked pharynx regeneration but had no effect on the regeneration of other organs," says Adler.

High resolution microscopy analysis showed that stem cells ramped up FoxA expression soon after they converged on the amputation site. "Currently, we think that FoxA triggers a cascade of gene expression that drives stem cells to produce all of the different cells of the pharynx, including muscle, neurons, and epithelial cells," says Adler. "The next question is how FoxA gets stimulated in the first place in only some stem cells."

Researchers knew previously that during embryogenesis FoxA initiates formation of endoderm-derived organs in species as diverse as mouse and roundworms. The new work suggests that regenerating tissues exploit those evolutionarily ancient gene expression pathways. "Engulfing food is one thing that defines an animal," says Snchez Alvarado. "This means that organisms from humans to flatworms use a common toolbox to build a digestive system, one that has been shared since animals became multicellular."

A fortuitous (in hindsight) setback facilitated the work. As a graduate student studying the roundworm C. elegans, Adler decided to test effects of roundworm anesthetics on flatworms. One, a sodium azide bath, put planaria to sleep but made their pharynxes drop off. Aghast, Adler soon realized that the azide solution (which planaria survived) left a uniform, minimally-destructive lesion. Thus was born the "selective chemical amputation method", allowing large-scale analysis and reliable quantification of results and freeing researchers from tedious hours at a dissecting microscope.

Read more:
Planaria deploy an ancient gene expression program in the course of organ regeneration

Contact Information

Available for logged-in reporters only

Newswise NEW YORK, NY (April 9, 2014) Dr. Mahendra Rao, who has directed the Center for Regenerative Medicine at the National Institutes of Health (NIH CRM) since 2010, will join The New York Stem Cell Foundation (NYSCF) Research Institute as its Vice President for Regenerative Medicine, a newly created position, Susan Solomon, NYSCF Chief Executive Officer, announced today.

Dr. Rao, who holds an MD degree and a PhD in developmental neurobiology, is one of the nations most prominent stem cell scientists. He has over twenty years of experience in all aspects of the stem cell field including government, academia, and business. Before joining the NIH, Dr. Rao spent six years as the vice president of Regenerative Medicine at Life Technologies, Inc. (now Thermo Fisher Scientific) after serving as the chief of Neurosciences at the National Institute on Aging and co-founding Q Therapeutics, a neural stem cell company based in Utah. Dr. Rao is tenured at the University of Utah School of Medicine in both Neurobiology and Anatomy and has over twenty submitted and ten issued patents.

Dr. Raos expertise in translational research, academia, and industry make him a valuable asset in our mission to take stem cell research from the laboratory to the clinic in order to find cures for the diseases that affect those we love, Solomon said. We are delighted to have him on board.

Solomon said that recruiting Dr. Rao is a major coup for NYSCF as it builds on its existing successes and carries out its strategic goals. Dr. Raos expertise and experience in setting up a company and in leading the translational effort at NIH will complement their expertise in automation and high-throughput induced pluripotent stem (iPS) cell generation.

I am enthused about NYSCFs efforts to generate high-quality stem cell lines and partner with the pharma and academic communities. I am excited to be joining them to advance their goals, said Dr. Rao.

In addition to his business career, Dr. Rao has served on scientific advisory boards, editorial boards and review panels and on committees including as the U.S. Food and Drug Administrations Cellular, Tissue, and Gene Therapies Advisory Committee chair and as the California Institute of Regenerative Medicine and International Society for Stem Cell Research liaison to the International Society for Cellular Therapy. Currently, he sits on the board of Cesca Therapeutics, Inc. and serves as the Chief Strategy Officer and Chairman of the Scientific Advisory Board at Q Therapeutics.

"Mahendra is a widely-recognized and accomplished leader in stem cell research. He will be a major asset for NYSCF as we continue to develop new therapeutics for patients," said Dr. Zach Hall, NYSCF Board Member and former Director of National Institute of Neurological Disorders and Stroke.

About The New York Stem Cell Foundation

Go here to see the original:
Mahendra Rao Joins The New York Stem Cell Foundation Research Institute

Bradley J. Fikes

Stem-cell biologist Mahendra Rao expected five projects to receive support to set up clinical trials.

Stem-cell researchers at the US National Institutes of Health (NIH) have been left frustrated and confused following the demise of the agencys Center for Regenerative Medicine (CRM). The intramural programmes director, stem-cell biologist Mahendra Rao, left the NIH, in Bethesda, Maryland, on 28March, and the centres website was taken down on 4 April. Although no official announcement had been made at the time Nature went to press, NIH officials say that they are rethinking how they will conduct in-house stem-cell research.

Researchers affiliated with the centre say that they have been left in the dark. When contacted by Nature on 7April, George Daley, a stem-cell biologist at Harvard Medical School in Boston, Massachusetts, and a member of the centres external advisory board, said that he had not yet been told of Raos departure or the centres closure.

The CRM was established in 2010 to centralize the NIHs stem-cell programme. Its goal was to develop useful therapies from induced pluripotent stem (iPS) cells adult cells that have been converted into embryonic-like stem cells and shepherd them towards clinical trials and regulatory approval. Its budget was intended to be $52million over seven years.

Rao took the helm in 2011. Relations seem to have soured last month owing to an NIH decision to award funding to only one project aiming to move iPS cells into a clinical trial. Rao says he resigned after this became clear. He says that he had hoped that five trials would be funded, especially because the centre had already sorted out complex issues relating to tissue sources, patents and informed consent.

James Anderson, director of the NIHs Division of Program Coordination, Planning, and Strategic Initiatives, which administered the CRM, counters that only one application that made by Kapil Bharti of the National Eye Institute in Bethesda and his colleagues received a high enough score from an external review board to justify continued funding. The team aims to use iPS cells to treat age-related macular degeneration of the retina, and hopes to commence human trials within a few years. Several other proposals, which involved the treatment of cardiac disease, cancer and Parkinsons disease, will not receive funding to ready them for clinical trials. Anderson stresses that Bhartis trial will not be affected by the CRMs closure.

NIH

Therapies based on induced pluripotent stem cells, here differentiating into retinal cells on a scaffold, were the focus of the Center for Regenerative Medicine.

Other human iPS-cell trials are further along. For example, one on macular degeneration designed by Masayo Takahashi at the RIKEN Center for Developmental Biology in Kobe, Japan, began recruiting patients last August.

Link:
NIH stem-cell programme closes

A doctor offering stem cell therapy may face charges for the death of a cancer patient who allegedly underwent treatment similar to that administered to former president and incumbent Pampanga Rep. Gloria Macapagal-Arroyo.

This was after it was found out that she is not a licensed doctor in the Philippines.

A report on GMA News TV's "News To Go" on Wednesday said a complaint has been filed against Dr. Antonia Carandang-Park at the National Bureau of Investigation (NBI) by Bernard Tan, who claims that his daughter, Kate, died after going through the said alternative treatment.Cancer patient Kate Tan received stem cell therapy from Dr. Antonia Carandang-Park, Gloria Arroyo's doctor.

Park owns the Tagaytay-based Green & Young Health and Wellness Center where Arroyoburdened by persistent trouble with her cervical spinesought treatment in 2012.

In an interview with GMA News, Tan said his daughter, who had Hodgkin's lymphoma (a type of cancer of the blood), was given "the same treatment that [Park] did with Gloria," which included "juicing diet, vegetable diet... acupuncture coffee enema, at 'yun na nga, stem cell."

Stem cell therapy introduces new adult stem cells into damaged tissue in order to treat disease or injury.

"Ang sabi niya, 'Give me three months, magaling na 'yan,'" Tan told GMA News. He added that his family was easily convinced to take their daughter to Park's wellness center because "Presidente na ng Pilipinas ang pumunta doon."

"Siguro naman na-scrutinize na nila 'yan, na-background check na nila 'yan," he said. "Kumbaga, 'yung credibility no'n, nag-build up na."

Kate was fed nothing but bananas and vegetable juices for three months, and had eight rounds of "embryonic" stem cell treatment, he said.

However, the 23-year-old lost even more weight, prompting the family to seek the assistance of a different doctor. Kate had eight rounds of 'embryonic' stem cell treatment, her father Bernard Tan said.Seven months later, in July 2013, Kate passed away.

Read the rest here:
Gloria Arroyos stem cell therapy doc blamed for cancer patient's death

(PRWEB) April 08, 2014

CELL SURGICAL NETWORK

Originating in California, CSN is the worlds largest cell surgical network and first multidisciplinary Regenerative Medicine group. CSN is collaborating with the Australian Adult Stem Cell Foundation to bring the research network to Australia.

CSN HAS OVER 40 LOCATIONS within the United States and several more worldwide. CSN has recently been launched in Australia with hand selected approved board certified Physicians. The ASCF has played an important role to identifying physicians who are passionate about regenerative and integrated medicine with a strong interest in SVF cell transplants.

INTERNATIONAL PHYSICIAN GROUP- Physicians belonging to the CSN network join an international network of Board certified Physicians, creating a multidisciplinary team where they receive training, technology and IP transfer, education and support for physicians and staff, access to IRB approved research protocols, the opportunity to submit their own protocols for IRB approval, website presence, and access to a university quality research database that collects outcomes from all sites.

SVF PROCUREMENT- The CSN SVF isolation system is a completely closed sterile surgical procedure. There are no laboratory requirements (e.g. laminar flow hood or otherwise) avoiding issues of GMP maintenance or possible cross contamination from laboratory handling. Further, the unique double filtration system avoids any risks of Pulmonary Emboli (PE) or problems due to particulate matter. The CSN has over the last 4 years researched and designed equipment that supports new requirements supported by the FDA/TGA. As the CSN system is a closed sterile surgical system it can be done in a doctors office and adheres to FDA/TGA regulations.

IRB STUDIES- Areas of study by the Cell Surgical Network include Orthopedics, Urology, Neurology, Cardiac/Pulmonary, Auto-Immune Diseases, Lichen Sclerosis, Ophthalmology. See http://www.stemcellrevolution.com

JOINING CELL SURGICAL NETWORK - Physicians interested in participating in the Cell Surgical Network please contact Chris Lindholm for more information by emailing clindholm(at)cellsurgicalnetwork(dot)com or phone 800-231-0407.

Read this article:
Cell Surgical Network Opening in Australia

Regulated information 3 April, 2014

TiGenix licenses exclusive marketing and distribution rights for ChondroCelect to Sobi

Sobi to assume responsibility for the commercialisation of ChondroCelect in existing and new markets in Europe and beyond

Sobi's considerable expertise and resources will enhance the availability of ChondroCelect to many more patients in many more countries

TiGenix to focus its resources on developing its pipeline of allogeneic treatments using expanded adipose-derived stem cells (eASC's)

Leuven (BELGIUM) - 3 April, 2014 -TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it has licensed the marketing and distribution of ChondroCelect, the cell-based medicinal product for the repair of cartilage defects of the knee, to the international specialty healthcare company dedicated to rare diseases, Swedish Orphan Biovitrum AB ('Sobi', NASDAQ OMX Stockholm: SOBI).

ChondroCelect was the first cell-based product to be approved in Europe. It is currently available for patients and reimbursed in Belgium, the Netherlands and Spain. Sales of ChondroCelect in 2013 were Euro 4.3 million, a growth of 25% on a like-for-like basis over 2012.

Sobi will continue to market and distribute the product where it is currently available and has also acquired the exclusive rights to expand the product's availability to patients in multiple additional territories, including the rest of the European Union, Norway, Switzerland, Turkey, and Russia, plus the countries of the Middle East and North Africa.

TiGenix will receive a royalty of 22% of the net sales of ChondroCelect in the first year of the agreement, and 20% of the net sales of ChondroCelect thereafter. There will be no upfront or milestone payments. The agreement will take effect on 1 June 2014, and has a duration of 10 years.

"We are delighted to reach this agreement with Sobi", said Eduardo Bravo, CEO of TiGenix. "With its experience of marketing and distributing specialty products, and with its human and financial resources, Sobi has the ability to bring ChondroCelect to a far greater number of patients in many more countries. This then allows TiGenix to focus its human and financial resources on the development of its platform and pipeline of allogeneic treatments using expanded adipose-derived stem cells (eASC's) for the benefit of patients suffering from a range of inflammatory and immunological conditions."

Follow this link:
TiGenix : licenses exclusive marketing and distribution rights for ChondroCelect to Sobi